ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults

摘要

Osteoporosis is a devastating disease that may lead to significant morbidity and mortality from resultant fractures.1–3 The efficacy of medications as one method to prevent and treat osteoporosis and avert future fractures, particularly vertebral fractures, is well documented in large clinical trials. However, despite this evidence, many patients at risk for osteoporosis are not screened or treated.4–8 Screening for osteoporosis is considered a quality-of-care indicator by the Centers for Medicare and Medicaid Services and the National Committee for Quality Assurance.9,10 The American Society of Health-System Pharmacists (ASHP) believes that all women age 65 years or older, postmenopausal women younger than age 65 years who have an increased risk of developing osteoporosis, all adult women with a history of nontraumatic fracture, and men with a significant risk of fracture should be screened for osteoporosis and treated, if indicated.